Bexson Biomedical Closes $4.8M Series A Financing To Develop Wearable Ketamine Technology
Pharmaceutical startup Bexson Biomedical confirmed Monday the closing an oversubscribed Series A funding round.
The $4.8 million raise was led by Greyhouse Partners' Noetic Psychedelic Fund.
